Shots:

• The approval is based on P-III KEYNOTE-407 study assessing Keytruda + carboplatin/nab paclitaxel vs carboplatin/nab paclitaxel monothx. in ratio (1:1) in patients with msqNSCLC regardless of PD-L1 expression 
• The P-III KEYNOTE-407 results: ORR (58% vs 38%); mDOR (7.7mos. vs 4.8mos.); improves PFS with reduction in death (44%)- improvement in OS (36%)
• Keytruda (pembrolizumab) 200mg IV is a mAb- used as an anti-D-L1 therapy that blocks the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2- further activating T lymphocytes and has received FDA’s approval for the same indication on October 30- 2018

Ref: Merck | Image: Merck